Trial Profile
A Randomized, Double-Blind, Multicentre, Phase II Controlled Trial Assessing Zactima (Vandetanib) Against Placebo in Prolonging the Off-Treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ZENITH
- 09 Dec 2010 Planned End Date changed from 1 Apr 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 03 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Dec 2009 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.